Casibrain secures tens of millions in Series B funding, deepens BCI industry chain presence

Recently, Casibrain, a high-end medical device enterprise incubated by the Institute of Automation of the Chinese Academy of Sciences, officially announced the completion of a Series B financing round totaling tens of millions of RMB. This financing round was led by Sunz Fund, a well-known Chinese domestic investment institution, with WinX Capital acting as the long-term exclusive financial advisor. This capital injection will fully support Casibrain in strengthening its position across the brain-computer interface industry chain, closely aligning with the development direction of "brain-computer interfaces" as a future industry outlined in China's "15th Five-Year Plan." It will accelerate the clinical translation and industrial implementation of cutting-edge technologies, contributing to the establishment of an autonomous and controllable industrial ecosystem in China's brain-computer interface sector.

As a National High-Tech Enterprise, a Zhongguancun High-Tech Enterprise, and a Beijing "Specialized, High-End and Innovation-Driven" Small and Medium-sized Enterprise, Casibrain was founded in 2017. Casibrain has consistently adhered to its "brain-centric" R&D philosophy and its corporate mission of "Precision in Brain Diagnostics, Commitment to Brain Protection," deeply engaging in the translation and industrialization of brain-computer interface technologies into medical devices.

Unlike pursuits of "conceptual" R&D, Casibrain remains grounded in clinical scenarios. Casibrain maintains deep collaborations with top-tier domestic medical institutions such as Xuanwu Hospital and Tiantan Hospital, both affiliated with Capital Medical University, to precisely capture core clinical needs in areas including perioperative intensive care, stroke rehabilitation, and functional substitution for spinal cord injury. From intelligent real-time monitoring for stroke patients, to non-invasive monitoring of cerebral oxygenation for critically ill patients, and to cranial protection, the development of each product stems from clinical pain points, and every technological iteration is tailored to the actual usage scenarios of medical staff and patients. This approach ensures that brain-computer interface technologies move beyond the laboratory to become reliable, implementable, and generalizable clinical diagnostic and therapeutic devices.

Casibrain has successfully established a "Brain-Computer Interface + Artificial Intelligence" technology foundation. Centered on this, it has formed a comprehensive layout covering the entire chain from brain-computer R&D and product manufacturing to clinical application, effectively spanning from brain-computer interfaces to brain-related medical devices. This has resulted in three product development directions targeting clinical departments such as anesthesiology/intensive care, stroke centers, and neurosurgery. Leveraging optics and electronics as a foundation, and integrating cutting-edge brain-computer interface technologies, Casibrain has independently developed innovative products, including the world's only non-invasive whole-brain multi-channel cerebral oximeter. This device addresses the critical need for perioperative monitoring and treatment in stroke care. Another innovation, the world's only synchronous optoelectric brain functional imager, is poised to revolutionize surgical outcomes in functional neurosurgery. 

All core products possess fully independent intellectual property rights, breaking the foreign technological monopoly in the field of advanced brain functional devices. To date, Casibrain has received recognition for two innovative medical devices from the National Medical Products Administration (NMPA), obtained eight domestic medical device registration certificates in China, and secured CE certification for the European market. Its products have been adopted in over 600 hospitals both in China and internationally.